Atty. Dkt. No. 041673-2007

In the Specification:

Please substitute the paragraph beginning at page 3, line 1, with the following replacement paragraph:

-- The invention therefore provides Super-Sog (amino acids 1-292 of Sog) and active variants thereof. Such variants include a recombinant Super-Sog peptide which includes 33 amino acids encoded by the pUAS expression vector; a Super-Sog peptide which includes a mutation (W→A) at residue 105 in the CR-1 sequence; and a Super-Sog peptide which terminates 5' of the CR-1 sequence at residue 346. Such variants also include Super-Sog with 5' modifications, such as modifications to the Tolloid protease cleavage site, addition of other peptides and inclusion of additional 5' regions of Sog (e.g., CR-2). --

Please delete the paragraph beginning at page 3, line 23, referencing Figure 1.

Please delete the paragraph beginning at page 3, line 28, referencing Figure 2.

Please delete the paragraph beginning at page 4, line 1, referencing Figure 3.

Please delete the paragraph beginning at page 4, line 5, referencing Figure 4.

Please delete the paragraph beginning at page 4, line 8, referencing Figure 5.

Please delete the paragraph beginning at page 4, line 11, referencing Figure 6.

Please amend the sentence beginning at page 5, line 9 to delete the reference at line 10 to "(Fig. 1)", and in line 11 to "(Fig. 6)".

Please substitute the paragraph beginning at page 5, line 13, with the following replacement paragraph:

-- Given their similarity in structure, it would be reasonably expected that any *Dpp* inhibitory activity conferred on the Sog protein by the CR repeats would be comparable in quality. It was therefore a surprise to find that a peptide encoded by CR-1 (Super-Sog) has greater Dpp inhibitory activity in certain respects than wild-type Sog. --

Please substitute the paragraph beginning at page 6, line 16, with the following replacement paragraph:

-- Super-Sog is prepared as a purified peptide fragment from Sog, expressed as a recombinant peptide using, for example, the coding sequences for amino acids 1-292 of Sog, or synthesized chemically. Techniques for production of peptides according to each of these methods are well-known in the art and so will only be described briefly here. --

Please substitute the paragraph beginning at page 7, line 14, with the following replacement paragraph:

-- Recombinant Super-Sog can also be produced *in vitro* or *in vivo* through expression of a polynucleotide sequence which encodes Super-Sog. In general, prokaryotes are used for cloning of DNA sequences in constructing recombinant expression vectors. For example, *E. coli* K12 strain 294 (ATCC Accession No. 31446) may be particularly useful. Prokaryotes also are used for expression. The aforementioned strain, as well as *E. coli* W3110 (ATTC Accession No. 27325), bacilli such as *Bacillus subtilus,* and other enterobacteriaceae such as *Salmonella typhimurium* or *Serratia marcescans*, and various *pseudomonas* species may also be used for expression. --

Please amend the sentence beginning at page 20, line 6, to delete the reference in line 9 to "(FIG. 3)".

In the Claims:

Please amend Claim 1 to read as follows:

1. An isolated or purified polynucleotide encoding amino acids 1-292 of the *Drosophilia* Sog protein.